Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Leuk Res. 2019 Jun 17;83:106172. doi: 10.1016/j.leukres.2019.106172

Table 1.

Patient disposition.

5/14 schedule
150–210 mg/day OPZ
2/7 schedule
210–330 mg/day OPZ

Number of patients enrolled 19 46
Continuing treatment 0 8 (17.4)
Discontinued treatment 19 (100) 38 (82.6)
Adverse event 11 (57.9) 12 (26.1)
Disease progression 5 (26.3) 19 (41.3)
Lost to follow-up 0 1 (2.2)
PI decision 1 (5.3) 2 (4.3)
Patient request 2 (10.5) 4 (8.7)

OPZ, oprozomib; PI, principal investigator.